CN117915888A - Anti-acne use - Google Patents

Anti-acne use Download PDF

Info

Publication number
CN117915888A
CN117915888A CN202280060824.0A CN202280060824A CN117915888A CN 117915888 A CN117915888 A CN 117915888A CN 202280060824 A CN202280060824 A CN 202280060824A CN 117915888 A CN117915888 A CN 117915888A
Authority
CN
China
Prior art keywords
acid
salicylic acid
total
combination
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280060824.0A
Other languages
Chinese (zh)
Inventor
厉峥嵘
杨舒琪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever IP Holdings BV
Original Assignee
Unilever IP Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever IP Holdings BV filed Critical Unilever IP Holdings BV
Publication of CN117915888A publication Critical patent/CN117915888A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a method for preparing (a): c 8 to C 20 fatty acids and/or salts thereof and (b): use of salicylic acid and/or a combination of salicylic acid derivatives as an anti-acne or antibacterial agent in a weight ratio of total (a) to total (b) of less than 1.7:1.

Description

Anti-acne use
Technical Field
The present invention relates to a novel use of a combination of fatty acids and/or salts thereof and salicylic acid and/or salicylic acid derivatives in specific ratios. Such a combination could unexpectedly provide synergistic anti-acne benefits.
Background
Acne, also known as acne vulgaris, is a common skin condition that affects almost all teenagers and adults at some point in life. Acne is observed to occur generally in areas rich in sebaceous glands such as the face, neck and back. Propionibacterium acnes (p.acnes) are also involved in the occurrence of acne. It resides in the sebaceous glands. Propionibacterium acnes uses sebum and byproducts from surrounding skin tissue as a source of energy and nutrients, resulting in acne or acne vulgaris.
Although many methods of treating acne have been developed, there remains a need to improve the efficacy against acne. Accordingly, the present inventors have developed the use of a combination of C 8 to C 20 fatty acids and/or salts thereof with salicylic acid and/or salicylic acid derivatives in a specific weight ratio as an anti-acne agent. Surprisingly, it has been found that such compositions are capable of providing synergistic anti-acne benefits.
Disclosure of Invention
In a first aspect, the invention relates to (a) for use as an anti-acne or antibacterial agent: c 8 to C 20 fatty acids and/or salts thereof and (b): a combination of salicylic acid and/or salicylic acid derivatives having a weight ratio of total (a) to total (b) of less than 1.7:1, wherein the fatty acid is an unsubstituted saturated fatty acid.
In a second aspect, the present invention relates to the use of a cosmetic composition for providing an anti-acne or anti-bacterial benefit, wherein the cosmetic composition comprises as anti-acne or anti-bacterial agent (a): c 8 to C 20 fatty acids and/or salts thereof and (b): a combination of salicylic acid and/or salicylic acid derivatives having a weight ratio of total (a) to total (b) of less than 1.7:1, wherein the fatty acid is an unsubstituted saturated fatty acid.
In a third aspect, the present invention relates to a cosmetic composition comprising (a) for providing anti-acne or antibacterial benefits: c 8 to C 20 fatty acids and/or salts thereof and (b): a combination of salicylic acid and/or salicylic acid derivatives having a weight ratio of total (a) to total (b) of less than 1.7:1, wherein the fatty acid is an unsubstituted saturated fatty acid.
In a fourth aspect, the present invention relates to (a): c 8 to C 20 fatty acids and/or salts thereof and (b): use of a combination of salicylic acid and/or salicylic acid derivatives in a method for providing an anti-acne or anti-bacterial benefit, the weight ratio of total (a) to total (b) being less than 1.7:1, the method comprising topically applying a cosmetic composition comprising said combination, the fatty acid being an unsubstituted saturated fatty acid.
All other aspects of the invention will become more apparent upon consideration of the following detailed description and examples.
Detailed Description
Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and/or use are optionally to be understood as modified by the word "about".
All amounts are by weight of the composition unless otherwise indicated.
It should be noted that any particular upper value may be associated with any particular lower value when specifying any range of values.
For the avoidance of doubt, the word "comprising" is intended to mean "including", but not necessarily "consisting of … …" or "consisting of … …". In other words, the listed steps or options need not be exhaustive.
The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the mutually multiply dependent claims, irrespective of the fact that the claims may exist without multiple dependencies or redundancies.
If a feature is disclosed with respect to a particular aspect of the invention (e.g., a composition of the invention), that disclosure should also be considered as applicable to any other aspect of the invention (e.g., a method of the invention), mutatis mutandis.
The present invention also provides (a): c 8 to C 20 fatty acids and/or salts thereof and (b): use of salicylic acid and/or a combination of salicylic acid derivatives in the manufacture of a medicament for providing anti-acne or antibacterial function in a weight ratio of total (a) to total (b) of less than 1.7:1.
The invention also provides a method for preparing (a): c 8 to C 20 fatty acids and/or salts thereof and (b): use of salicylic acid and/or a combination of salicylic acid derivatives as an anti-acne or antibacterial agent in a weight ratio of total (a) to total (b) of less than 1.7:1.
Preferably, the use is non-therapeutic. Preferably, the method is non-therapeutic. The term non-therapeutic generally refers to use for cosmetic purposes, not for curative or therapeutic purposes.
Combination of two or more kinds of materials
Preferably, the fatty acid comprises a C 8 to C 16 fatty acid, more preferably a C 10 to C 14 fatty acid. Preferably, the fatty acid has a linear chain of 8 to 16, preferably 10 to 14 carbon atoms in length. Fatty acids are unsubstituted saturated fatty acids. Preferably, the fatty acid comprises dodecanoic acid, stearic acid, tetradecanoic acid, oleic acid, linoleic acid, linolenic acid, or combinations thereof. More preferably, the fatty acid comprises dodecanoic acid. Even more preferably, the fatty acid is dodecanoic acid. The fatty acid salt is preferably the sodium salt of a fatty acid.
Preferably, (a) is dodecanoic acid and/or a salt of dodecanoic acid. More preferably, (a) is dodecanoic acid.
Salicylic acid derivatives as used herein generally include esters and/or salts of salicylic acid. Preferably, the salicylic acid derivative is an ester and/or salt of salicylic acid. More preferably, the salicylic acid derivative is a salicylate. Preferably, the salicylic acid derivative is selected from acetaminosalol, aspirin, balsalazide, benorilate, calcium acetylsalicylate, diflunisal, fendossal, gentisic acid, glycol salicylate, imidazole salicylate, lisicaline, mesalamine, salicylmorpholine, 1-naphthyl salicylate, olsalazine, pasamide, phenylacetyl salicylate, phenyl salicylate, salicylamide O-acetic acid, salicylsulfuric acid, bissalicylate, sodium salicylate, sulfasalazine, or a combination thereof. More preferably, the salicylic acid derivative is sodium salicylate.
Preferably, (b) is salicylic acid and/or a salt of salicylic acid. More preferably, (b) is salicylic acid.
Preferably, the weight ratio of the total weight of C 8 to C 20 fatty acids and salts thereof to the total weight of salicylic acid and salicylic acid derivatives is from 0.1:1 to 1.7:1, more preferably from 0.2:1 to 1.6:1, even more preferably from 0.4:1 to 1.5:1, even more preferably from 0.6:1 to 1.4:1, most preferably from 0.7:1 to 1.3:1.
Preferably, the combination is (a): c 8 to C 20 fatty acid and (b): salicylic acid or a combination of salicylates having a weight ratio of total (a) to total (b) of less than 1.7:1. Preferably, the weight ratio of C 8 to C 20 fatty acids to total salicylic acid and salicylate weight is from 0.1:1 to 1.7:1, more preferably from 0.2:1 to 1.6:1, even more preferably from 0.4:1 to 1.5:1, even more preferably from 0.6:1 to 1.4:1, most preferably from 0.7:1 to 1.3:1.
Preferably, the combination is (a): dodecanoic acid and/or dodecanoate and (b): a combination of salicylic acid and/or salicylate in a weight ratio of total (a) to total (b) of less than 1.7:1. Preferably, the weight ratio of the total weight of dodecanoic acid and dodecanoic acid salt to the total weight of salicylic acid and salicylic acid salt is from 0.1:1 to 1.7:1, more preferably from 0.2:1 to 1.6:1, even more preferably from 0.4:1 to 1.5:1, even more preferably from 0.6:1 to 1.4:1, most preferably from 0.7:1 to 1.3:1.
Preferably, the combination is (a): dodecanoic acid and (b): the combination of salicylic acid having a weight ratio of total (a) to total (b) of less than 1.7:1. Preferably, the weight ratio of dodecanoic acid to salicylic acid is from 0.1:1 to 1.7:1, more preferably from 0.2:1 to 1.6:1, even more preferably from 0.4:1 to 1.5:1, even more preferably from 0.6:1 to 1.4:1, most preferably from 0.7:1 to 1.3:1.
For clarity, the combination of the present invention generally has better antibacterial, especially anti-acne, benefits than a combination of (a) and (b) in which the weight ratio of (a), (b) or total (a) to total (b) is not less than 1.7:1.
Cosmetic composition
Preferably, (a) is present in the cosmetic composition: c 8 to C 20 fatty acids and/or salts thereof and (b): salicylic acid and/or salicylic acid derivatives. Preferably, the amount of C 8 to C 20 fatty acids and salts thereof is from 0.01 to 8%, more preferably from 0.05 to 5%, even more preferably from 0.1 to 2%, most preferably from 0.2 to 1.2% by weight of the composition. Preferably, the salicylic acid and salicylic acid derivatives are present in an amount of 0.01-8%, more preferably 0.05-5%, even more preferably 0.1-2%, most preferably 0.2-1.2% by weight of the composition.
Preferably, the combination is (a): c 8 to C 20 fatty acid and (b): a combination of salicylic acids having a weight ratio of total (a) to total (b) of less than 1.7:1, and the combination being present in a cosmetic composition. Preferably, the amount of C 8 to C 20 fatty acids is 0.01 to 8%, more preferably 0.05 to 5%, even more preferably 0.1 to 2%, most preferably 0.2 to 1.2% by weight of the composition. Preferably, the amount of salicylic acid is from 0.01 to 8%, more preferably from 0.05 to 5%, even more preferably from 0.1 to 2%, most preferably from 0.2 to 1.2% by weight of the composition.
Preferably, the combination is (a): dodecanoic acid and/or dodecanoate and (b): a composition of salicylic acid and/or salicylate having a weight ratio of total (a) to total (b) of less than 1.7:1, and the combination being present in a cosmetic composition. Preferably, the total amount of dodecanoic acid and dodecanoic acid salt is 0.01-8%, more preferably 0.05-5%, even more preferably 0.1-2%, most preferably 0.2-1.2% by weight of the composition. Preferably, the amount of salicylic acid and salicylate is from 0.01 to 8%, more preferably from 0.05 to 5%, even more preferably from 0.1 to 2%, most preferably from 0.2 to 1.2% by weight of the composition.
Preferably, the combination is (a): dodecanoic acid and (b): a combination of salicylic acids having a weight ratio of total (a) to total (b) of less than 1.7:1, and the combination being present in a cosmetic composition. Preferably, the amount of dodecanoic acid is from 0.01 to 8%, more preferably from 0.05 to 5%, even more preferably from 0.1 to 2%, most preferably from 0.2 to 1.2% by weight of the composition. Preferably, the amount of salicylic acid is from 0.01 to 8%, more preferably from 0.05 to 5%, even more preferably from 0.1 to 2%, most preferably from 0.2 to 1.2% by weight of the composition.
The cosmetic compositions of the present invention generally provide better anti-acne and antibacterial benefits than cosmetic compositions that do not contain (a) and (b) in a weight ratio of total (a) to total (b) of less than 1.7:1.
The composition preferably comprises a cleansing surfactant. More than one cleansing surfactant may be included in the composition. The cleansing surfactant may be selected from the group consisting of soaps, non-soap anions, cations, nonionic, amphoteric surfactants, and mixtures thereof. Many suitable surface-active compounds are available and are well described in the literature, for example, "surface-ACTIVE AGENTS AND DETERGENTS" by Schwartz, perry and Berch, volumes I and II. Preferred surface-active compounds that can be used are soaps, non-soap anions, nonionic surfactants, amphoteric surfactants or mixtures thereof.
Suitable non-soap anionic surfactants include linear alkylbenzene sulphonates, primary and secondary alkyl sulphates, in particular C 8 to C 15 primary alkyl sulphates; alkyl ether sulfate; olefin sulfonate; alkyl xylene sulfonate; dialkyl sulfosuccinates; fatty acid ester sulfonate; or a mixture thereof. Sodium salts are generally preferred.
The most preferred non-soap anionic surfactant is linear alkylbenzene sulfonate, particularly linear alkylbenzene sulfonate having an alkyl chain length of from C 8 to C 15. Preferably, the level of linear alkylbenzene sulfonate is from 0wt% to 30wt%, more preferably from 1wt% to 25wt%, most preferably from 2wt% to 15wt% of the total composition weight.
Nonionic surfactants that may be used include primary and secondary alcohol ethoxylates, particularly C 8 to C 20 aliphatic alcohols ethoxylated with an average of 1 to 20 moles of ethylene oxide per mole of alcohol, more particularly C 10 to C 15 primary and secondary aliphatic alcohols ethoxylated with an average of 1 to 10 moles of ethylene oxide per mole of alcohol. Non-ethoxylated nonionic surfactants include alkyl polyglycosides, glycerol monoethers, and polyhydroxyamides (glucamide). Preferably, the level of nonionic surfactant is from 0wt% to 30wt%, preferably from 1wt% to 25wt%, most preferably from 2wt% to 15wt% of the weight of the fully formulated composition comprising microcapsules of the present invention.
Suitable amphoteric surfactants are preferably betaine surfactants. Examples of suitable amphoteric surfactants include, but are not limited to, alkyl betaines, alkyl amidobetaines, alkyl sulfobetaines, and alkyl amidosulfobetaines; preferably those having 8 to about 18 carbons in the alkyl and acyl groups. Preferably, the amount of amphoteric surfactant is from 0 to 20wt%, more preferably from 1 to 10wt% by weight of the composition.
Certain mono-alkyl cationic surfactants may also be included. Cationic surfactants that may be used include quaternary ammonium salts of the formula R 1R2R3R4N+X-, wherein the R group is a long or short hydrocarbon chain, typically alkyl, hydroxyalkyl or ethoxylated alkyl, and X is a counterion (e.g., a compound wherein R 1 is C 8-C22 alkyl, preferably C 8-C10 or C 12-C14 alkyl, R 2 is methyl, and R 3 and R 4, which may be the same or different, are methyl or hydroxyethyl); and cationic esters (e.g., choline esters).
The water-soluble skin benefit agent may optionally be formulated into the compositions of the present invention. A variety of water soluble skin benefit agents may be used and may be present at levels of from 0.1 to 50% by weight of the composition, but preferably from 1 to 30%. These materials include, but are not limited to, polyhydroxy alcohols. Preferred water-soluble skin benefit agents are glycerin, sorbitol and polyethylene glycol.
Non-water soluble skin benefit agents may also be formulated into the composition as conditioning and moisturizing agents. Examples include silicone oils; hydrocarbons such as liquid paraffin, petrolatum, microcrystalline wax and mineral oil; and vegetable triglycerides, such as sunflower seed oil and cottonseed oil.
Some compositions may comprise a thickener. These materials may be selected from the group consisting of cellulosics, natural gums, and acrylic polymers, but are not limited to this thickener type. The celluloses include sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof. Suitable gums include xanthan gum, pectin, karaya, agar, alginate, and combinations thereof. Acrylic thickeners include homopolymers and copolymers of acrylic acid and methacrylic acid, including carbomers, such as carbopol 1382, carbopol 982, ultrez, aqua SF-1 and Aqua SF-2 available from Lubrizol Corporation. The amount of thickener may be in the range of 0.01 to 3% by weight of active polymer (excluding solvent or water) in the composition.
Preservatives may desirably be incorporated into the compositions of the present invention to prevent the growth of potentially harmful microorganisms. Particularly preferred preservatives are phenoxyethanol, methylparaben, propylparaben, imidazolidinyl urea, sodium dehydroacetate and benzyl alcohol. The preservative should be selected in view of the use of the composition and the possible incompatibility between the preservative and the other ingredients. The preservative is preferably used in an amount ranging from 0.01% to 2% by weight of the composition.
A variety of other optional materials may be formulated into the composition. They may include: antimicrobial agents such as 2-hydroxy-4, 2',4' -trichlorodiphenyl ether (triclosan), 2, 6-dimethyl-4-hydroxychlorobenzene and 3, 4' -trichlorocarbanilide; sanding and exfoliating particles such as polyethylene and silica or alumina; a coolant, such as menthol; skin soothing agents such as aloe vera; and a colorant.
In addition, the composition of the present invention may further comprise 0.5 to 10% by weight of a chelating agent, such as tetrasodium ethylenediamine tetraacetate (EDTA), EHDP, or mixtures thereof; opacifiers and pearlizers, such as ethylene glycol distearate, titanium dioxide or Lytron 621 (styrene/acrylate copolymer); all of which can be used to enhance the appearance or performance of the product.
Preferably, the composition comprises water in an amount of at least 5% by weight of the composition, more preferably at least 25% by weight of the composition, even more preferably from 40% to 90%, even more preferably still at least 60% to 85%.
Preferably, the composition has a viscosity of at least 5 mPa-s, more preferably in the range of 8-10000 mPa-s, even more preferably 10 to 1000 mPa-s, most preferably 20 to 200 mPa-s, when measured at 20 ℃ at a relatively high shear rate of about 20s -1. Preferably, the composition is in liquid form.
Cosmetic composition means a composition suitable for topical application to human skin, preferably a rinse-off product. The term "rinse-off" as used herein in reference to a composition refers to a composition that is applied or smeared onto the skin and then rinsed off. The term "skin" as used herein includes skin on the face (except eyelids and lips), neck, chest, abdomen, back, arms, armpits, hands and legs. Preferably, "skin" refers to skin that includes the face (except the eyelids and lips) and underarms, more preferably skin refers to skin on the face except the lips and eyelids.
The following examples are provided to facilitate an understanding of the present invention. The examples are not intended to limit the scope of the claims.
Examples
Example 1
This example demonstrates the synergy between dodecanoic acid and salicylic acid in terms of anti-acne.
TABLE 1
* Significantly better than any of A, B, C (p < 0.05)
The zone of inhibition (ZOI) of the different samples against propionibacterium acnes (p.acnes) was tested. Samples were prepared according to table 1. mu.L of each sample or control sample (sterile distilled water) was dropped onto the same filter paper and all of these filter papers were dried. Cultures of Propionibacterium acnes were washed and diluted with PBS to a concentration of 1X 10 4 to 9X 10 4 cfu/mL of suspension. The suspension was spread evenly on nutrient agar medium plates with sterile swabs. The dry filter paper with the sample was applied closely to the plate at a sufficient distance. Plates were covered and incubated at 37℃for 16 to 18 hours. Samples that diffused into agar were assayed for their ability to create a zone of inhibition. The ZOI diameters for the different samples are recorded in table 1. The greater the ZOI, the better the anti-acne efficacy provided by the sample.
As is evident from table 1, sample 1 provided significantly better anti-acne efficacy than either of samples A, B and C. Surprisingly, it has been found that when combined in a weight ratio of dodecanoic acid to salicylic acid of less than 1.7:1, dodecanoic acid and salicylic acid are able to provide synergistic anti-acne benefits.
Example 2
This example demonstrates a composition comprising a combination of dodecanoic acid and salicylic acid.
Skin cleansing compositions were prepared according to table 2 by the following standard procedure.
TABLE 2
Example 3
This example demonstrates that there is no synergy between oleic acid and salicylic acid in the anti-acne benefits.
The experiment was performed in a similar manner as described in the examples, except that: i) Oleic acid was used instead of dodecanoic acid; ii) the concentration of Propionibacterium acnes used to test ZOI was 1X 10 8 to 9X 10 8 cfu/mL; iii) Plates were covered and incubated at 37℃for 46-48 hours. Table 3 shows the test results.
TABLE 3 Table 3
* Significantly lower than E (p < 0.05)
As shown in table 3, there was no synergistic anti-acne efficacy when oleic acid and salicylic acid were combined.

Claims (15)

1. (A) for use as an anti-acne or antibacterial agent: c 8 to C 20 fatty acids and/or salts thereof and (b): a combination of salicylic acid and/or salicylic acid derivatives having a weight ratio of total (a) to total (b) of less than 1.7:1, wherein the fatty acid is an unsubstituted saturated fatty acid.
2. The combination according to claim 1, wherein the fatty acid has a linear chain of 10 to 14 carbon atoms in length, preferably the fatty acid is dodecanoic acid.
3. A combination according to claim 1 or 2, wherein (b) is salicylic acid and/or a salicylate, preferably (b) is salicylic acid.
4. The combination according to any one of the preceding claims, wherein the weight ratio of the total weight of C 8 to C 20 fatty acids and salts thereof to the total weight of salicylic acid and salicylic acid derivatives is from 0.2:1 to 1.6:1, preferably from 0.7:1 to 1.3:1.
5. The combination of any one of the preceding claims, wherein the combination is (a): dodecanoic acid and/or a salt of dodecanoic acid and (b): salicylic acid and/or a combination of salts of salicylic acid in a weight ratio of total (a) to total (b) of less than 1.7:1.
6. The combination according to claim 5, wherein the weight ratio of the total weight of dodecanoic acid and salts of dodecanoic acid to the total weight of salicylic acid and salts of salicylic acid is from 0.2:1 to 1.6:1, preferably from 0.7:1 to 1.3:1.
7. The combination of any one of the preceding claims, wherein the combination is (a): dodecanoic acid and (b): the combination of salicylic acid having a weight ratio of total (a) to total (b) of less than 1.7:1.
8. The combination according to claim 7, wherein the weight ratio of the dodecanoic acid to the salicylic acid is from 0.2:1 to 1.6:1, preferably from 0.7:1 to 1.3:1.
9. The non-therapeutic use of a combination according to any one of the preceding claims as an anti-acne or antibacterial agent in a cosmetic composition, wherein the fatty acid is an unsubstituted saturated fatty acid.
10. Use of a cosmetic composition for providing an anti-acne or anti-bacterial benefit, wherein the cosmetic composition comprises (a) as an anti-acne or anti-bacterial agent: c 8 to C 20 fatty acids and/or salts thereof and (b): a combination of salicylic acid and/or salicylic acid derivatives having a weight ratio of total (a) to total (b) of less than 1.7:1, wherein the fatty acid is an unsubstituted saturated fatty acid.
11. A cosmetic composition comprising (a) for providing an anti-acne or antibacterial benefit: c 8 to C 20 fatty acids and/or salts thereof and (b): a combination of salicylic acid and/or salicylic acid derivatives having a weight ratio of total (a) to total (b) of less than 1.7:1, wherein the fatty acid is an unsubstituted saturated fatty acid.
12. (A) : c 8 to C 20 fatty acids and/or salts thereof and (b): use of a combination of salicylic acid and/or salicylic acid derivatives in a method of providing an anti-acne or anti-bacterial benefit in a weight ratio of total (a) to total (b) of less than 1.7:1, the method comprising topically applying a cosmetic composition comprising said combination, wherein the fatty acid is an unsubstituted saturated fatty acid.
13. The use, composition or method according to any of the preceding claims 9-12, wherein the total amount of C 8 to C 20 fatty acids and salts thereof is 0.01 to 8%, preferably 0.1 to 2% by weight of the composition, and the total amount of salicylic acid and salicylic acid derivatives is 0.01 to 8%, preferably 0.1 to 2% by weight of the composition.
14. The use, composition or method according to any of the preceding claims 9-13, wherein the total amount of dodecanoic acid and salts of dodecanoic acid is 0.01 to 8%, preferably 0.1 to 2% by weight of the composition and the total amount of salicylic acid and salicylic acid derivatives is 0.01 to 8%, preferably 0.1 to 2% by weight of the composition.
15. The use, composition or method according to any of the preceding claims 9 to 14, wherein the amount of dodecanoic acid is 0.01 to 8%, preferably 0.1 to 2% by weight of the composition and the amount of salicylic acid is 0.01 to 8%, preferably 0.1 to 2% by weight of the composition.
CN202280060824.0A 2021-09-10 2022-09-05 Anti-acne use Pending CN117915888A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021117556 2021-09-10
CNPCT/CN2021/117556 2021-09-10
EP21204604 2021-10-26
EP21204604.9 2021-10-26
PCT/EP2022/074554 WO2023036723A1 (en) 2021-09-10 2022-09-05 Use for anti-acne

Publications (1)

Publication Number Publication Date
CN117915888A true CN117915888A (en) 2024-04-19

Family

ID=83398191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280060824.0A Pending CN117915888A (en) 2021-09-10 2022-09-05 Anti-acne use

Country Status (2)

Country Link
CN (1) CN117915888A (en)
WO (1) WO2023036723A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619256B2 (en) * 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
GB201112657D0 (en) * 2011-07-22 2011-09-07 Lowe Nicholas J Compositions for treatment of skin disorders
CN108992389A (en) * 2018-10-23 2018-12-14 江苏朗沁科技有限公司 A kind of light spot dressing of anti-acne
CN113456570A (en) * 2021-07-23 2021-10-01 完美（广东）日用品有限公司 Acne-removing composition, acne-removing gel and preparation method thereof

Also Published As

Publication number Publication date
WO2023036723A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
CA2332474C (en) Low etoxyl sorbitan ester based keratinous materials washing compositions
US9833395B2 (en) Sustainable cold-dispersible pearlescent concentrate
EP3849504A1 (en) Personal cleansing compositions
EP2931243A2 (en) Reduction of ammonia odor in agents for dyeing and/or bleaching hair
CN113456570A (en) Acne-removing composition, acne-removing gel and preparation method thereof
CN117915888A (en) Anti-acne use
JP6564365B2 (en) Hair treatment composition
CN115279460A (en) Personal care compositions
EP3185962B1 (en) Multi-tonal one step dyeing process using a thickened pretreatment solution iii
EP4267100A1 (en) Personal care composition
TWI645849B (en) Use of coco polyether sulfate as antibacterial agent against P. acnes
WO2012121469A1 (en) Antibacterial or preserving composition containing 3-butoxy-1,2-propanediol
SK11482000A3 (en) Anti-enzyme compositions comprising ethylenediamine disuccinic acid
WO2016005209A1 (en) Use of spiculisporic acid and/or a salt thereof as antidandruff agent, and cosmetic treatment process employing same
JP2021506753A (en) Topical composition containing antibacterial lipids
DE60111199T2 (en) TOPICAL ANTIOXIDATIVE VITAMIN COMPOSITION FOR SKIN CARE
CN113365600B (en) Preservative systems and compositions containing them
KR100324630B1 (en) Hair-care cosmetic compositions having an effect of suppressing dandruff formation
CA3198782A1 (en) Personal care composition comprising glycinate surfactant, polyol and nonionic surfactant comprising alkyl glucoside
CA3197686A1 (en) Skin cleansing composition
CA3200827A1 (en) Personal care composition
US3029273A (en) Nitroalkyl dihalocarbanilates
CN117323273A (en) Antibacterial hand sanitizer containing plant extracts and preparation method thereof
WO2023245409A1 (en) Composition for cleansing the hair
KR20230114314A (en) Metal Containment Cosmetic Composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination